JP2015503608A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015503608A5 JP2015503608A5 JP2014551706A JP2014551706A JP2015503608A5 JP 2015503608 A5 JP2015503608 A5 JP 2015503608A5 JP 2014551706 A JP2014551706 A JP 2014551706A JP 2014551706 A JP2014551706 A JP 2014551706A JP 2015503608 A5 JP2015503608 A5 JP 2015503608A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- rnai agent
- beta
- composition
- catenin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 19
- 230000025458 RNA interference Effects 0.000 claims 18
- 125000003729 nucleotide group Chemical group 0.000 claims 14
- 230000000692 anti-sense Effects 0.000 claims 12
- 102000015735 beta Catenin Human genes 0.000 claims 11
- 108060000903 beta Catenin Proteins 0.000 claims 11
- 239000002773 nucleotide Substances 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 206010038389 Renal cancer Diseases 0.000 claims 6
- 201000010982 kidney cancer Diseases 0.000 claims 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- WQLVFSAGQJTQCK-VKROHFNGSA-N Diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 claims 4
- GMBQZIIUCVWOCD-WWASVFFGSA-N Sarsapogenine Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 GMBQZIIUCVWOCD-WWASVFFGSA-N 0.000 claims 4
- 229920000972 Sense strand Polymers 0.000 claims 4
- 150000001720 carbohydrates Chemical class 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 200000000019 wound Diseases 0.000 claims 4
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 206010017758 Gastric cancer Diseases 0.000 claims 3
- 206010025650 Malignant melanoma Diseases 0.000 claims 3
- 208000000172 Medulloblastoma Diseases 0.000 claims 3
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 3
- 208000001132 Osteoporosis Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 3
- 208000004210 Pressure Ulcer Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 210000000515 Tooth Anatomy 0.000 claims 3
- 208000008383 Wilms Tumor Diseases 0.000 claims 3
- 230000001780 adrenocortical Effects 0.000 claims 3
- 230000032683 aging Effects 0.000 claims 3
- 201000009030 carcinoma Diseases 0.000 claims 3
- 230000001684 chronic Effects 0.000 claims 3
- 201000011231 colorectal cancer Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 201000008026 nephroblastoma Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 201000000849 skin cancer Diseases 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- 201000002510 thyroid cancer Diseases 0.000 claims 3
- 201000005161 thyroid carcinoma Diseases 0.000 claims 3
- 210000001519 tissues Anatomy 0.000 claims 3
- 201000005290 uterine carcinosarcoma Diseases 0.000 claims 3
- 229920002101 Chitin Polymers 0.000 claims 2
- DJHJJVWPFGHIPH-OODMECLYSA-N Chitin Chemical compound O[C@@H]1C(NC(=O)C)[C@H](O)OC(CO)[C@H]1COC[C@H]1C(NC(C)=O)[C@@H](O)[C@H](COC[C@H]2C([C@@H](O)[C@H](O)C(CO)O2)NC(C)=O)C(CO)O1 DJHJJVWPFGHIPH-OODMECLYSA-N 0.000 claims 2
- 229920001661 Chitosan Polymers 0.000 claims 2
- 229940107161 Cholesterol Drugs 0.000 claims 2
- 229920000858 Cyclodextrin Polymers 0.000 claims 2
- 229920002307 Dextran Polymers 0.000 claims 2
- -1 Epi-Freedelanol Natural products 0.000 claims 2
- OFMXGFHWLZPCFL-ACRUQRPVSA-N Friedelan-3-one Natural products C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3CCC(=O)[C@H]1C OFMXGFHWLZPCFL-ACRUQRPVSA-N 0.000 claims 2
- 101710015954 HVA1 Proteins 0.000 claims 2
- 229920001202 Inulin Polymers 0.000 claims 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N Inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims 2
- 229940029339 Inulin Drugs 0.000 claims 2
- 101700065814 LEA2 Proteins 0.000 claims 2
- 101700021338 LEC Proteins 0.000 claims 2
- 101700077545 LECC Proteins 0.000 claims 2
- 101700028499 LECG Proteins 0.000 claims 2
- 101700063913 LECT Proteins 0.000 claims 2
- SMEROWZSTRWXGI-HVATVPOCSA-N Lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 claims 2
- 101700080605 NUC1 Proteins 0.000 claims 2
- 101710034340 Os04g0173800 Proteins 0.000 claims 2
- 229920001218 Pullulan Polymers 0.000 claims 2
- 239000004373 Pullulan Substances 0.000 claims 2
- 102000004338 Transferrin Human genes 0.000 claims 2
- 108090000901 Transferrin Proteins 0.000 claims 2
- 229940088594 Vitamin Drugs 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003431 cross linking reagent Substances 0.000 claims 2
- OFMXGFHWLZPCFL-SVRPQWSVSA-N friedelin Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3CCC(=O)[C@@H]1C OFMXGFHWLZPCFL-SVRPQWSVSA-N 0.000 claims 2
- 229920002674 hyaluronan Polymers 0.000 claims 2
- 229960003160 hyaluronic acid Drugs 0.000 claims 2
- 102000006495 integrins Human genes 0.000 claims 2
- 108010044426 integrins Proteins 0.000 claims 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims 2
- 101700036391 lecA Proteins 0.000 claims 2
- 239000002523 lectin Substances 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 150000002634 lipophilic molecules Chemical class 0.000 claims 2
- 101700001016 mbhA Proteins 0.000 claims 2
- 229920005615 natural polymer Polymers 0.000 claims 2
- 101700006494 nucA Proteins 0.000 claims 2
- 229920000768 polyamine Polymers 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 230000036678 protein binding Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 235000019423 pullulan Nutrition 0.000 claims 2
- 150000003230 pyrimidines Chemical class 0.000 claims 2
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 150000003505 terpenes Chemical class 0.000 claims 2
- 235000007586 terpenes Nutrition 0.000 claims 2
- 239000012581 transferrin Substances 0.000 claims 2
- 150000003648 triterpenes Chemical class 0.000 claims 2
- 239000011782 vitamin Substances 0.000 claims 2
- 235000013343 vitamin Nutrition 0.000 claims 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims 2
- 229930003231 vitamins Natural products 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
Claims (20)
- センス鎖とアンチセンス鎖とを含むＲＮＡｉ剤を含む組成物であって、アンチセンス鎖が、表１に示すベータ−カテニンに特異的なＲＮＡｉ剤のアンチセンス鎖と０、１、２または３ヌクレオチド異なる少なくとも１５の連続したヌクレオチドを含む、組成物。
- ベータ−カテニンに対する第２のＲＮＡｉ剤をさらに含む、請求項１に記載の組成物。
- ＲＮＡｉ剤が、少なくとも１つの改変骨格および／または少なくとも１つの２’−改変ヌクレオチドを含む、請求項１に記載の組成物。
- ＲＮＡｉ剤が、診断用化合物、レポーター基、架橋剤、ヌクレアーゼ耐性付与部分、天然または異常核酸塩基、親脂性分子、コレステロール、脂質、レクチン、ステロイド、ウバオール、ヘシゲニン、ジオスゲニン、テルペン、トリテルペン、サルササポゲニン、フリーデリン、エピフリーデラノール由来リトコール酸、ビタミン、炭水化物、デキストラン、プルラン、キチン、キトサン、合成炭水化物、オリゴ乳酸１５マー、天然ポリマー、低分子量または中分子量ポリマー、イヌリン、シクロデキストリン、ヒアルロン酸、タンパク質、タンパク質結合剤、インテグリンターゲティング分子、ポリカチオン、ペプチド、ポリアミン、模倣ペプチドおよび／またはトランスフェリンから選択される１または複数の作用剤にライゲーションされる、請求項１に記載の組成物。
- 第１鎖と第２鎖とを含むＲＮＡｉ剤を含む組成物であって、第１鎖および第２鎖が、表１に示すベータ−カテニンに特異的なＲＮＡｉ剤の第１鎖および第２鎖とそれぞれ０、１、２または３ヌクレオチド異なる少なくとも１５の連続したヌクレオチドを含む、組成物。
- ベータ−カテニンに対する第２のＲＮＡｉ剤を含む、請求項１に記載の組成物。
- ＲＮＡｉ剤が、ホスホロチオエートおよび／または２’−改変ヌクレオチドを含む、請求項１に記載の組成物。
- ＲＮＡｉ剤が、診断用化合物、レポーター基、架橋剤、ヌクレアーゼ耐性付与部分、天然または異常核酸塩基、親脂性分子、コレステロール、脂質、レクチン、ステロイド、ウバオール、ヘシゲニン、ジオスゲニン、テルペン、トリテルペン、サルササポゲニン、フリーデリン、エピフリーデラノール由来リトコール酸、ビタミン、炭水化物、デキストラン、プルラン、キチン、キトサン、合成炭水化物、オリゴ乳酸１５マー、天然ポリマー、低分子量または中分子量ポリマー、イヌリン、シクロデキストリン、ヒアルロン酸、タンパク質、タンパク質結合剤、インテグリンターゲティング分子、ポリカチオン、ペプチド、ポリアミン、模倣ペプチドおよび／またはトランスフェリンから選択される１または複数の作用剤にライゲーションされる、請求項１に記載の組成物。
- 個体においてベータ−カテニン関連疾患を処置するための医薬組成物であって、センス鎖とアンチセンス鎖とを含むＲＮＡｉ剤を含む治療有効量の組成物を含み、アンチセンス鎖が、表１に示すベータ−カテニンに特異的なＲＮＡｉ剤のアンチセンス鎖と０、１、２または３ヌクレオチド異なる少なくとも１５の連続したヌクレオチドを含む、医薬組成物。
- ベータ−カテニン関連疾患が、大腸腺腫症、結腸直腸癌、基底細胞癌腫、乳癌、腎癌、ウイルムス腫瘍、髄芽腫、卵巣癌、副腎皮質腫瘍、胃癌、肝癌、黒色腫、膵癌、前立腺癌、腎癌、異所性歯牙および味覚乳頭、皮膚癌、石灰化上皮腫、組織非形成性甲状腺癌腫および子宮癌肉腫、部分的無歯症、骨粗鬆症、老化、変性疾患、褥瘡、ならびに慢性創傷および創傷治癒障害から選択される、請求項９に記載の医薬組成物。
- 大腸腺腫症、結腸直腸癌、基底細胞癌腫、乳癌、腎癌、ウイルムス腫瘍、髄芽腫、卵巣癌、副腎皮質腫瘍、胃癌、肝癌、黒色腫、膵癌、前立腺癌、腎癌、異所性歯牙および味覚乳頭、皮膚癌、石灰化上皮腫、組織非形成性甲状腺癌腫および子宮癌肉腫、部分的無歯症、骨粗鬆症、老化、変性疾患、褥瘡および／または慢性創傷および創傷治癒障害のためのさらなる処置と共に用いるための、請求項９に記載の医薬組成物。
- ベータ−カテニンに対するさらなるＲＮＡｉ剤を含む、請求項１１に記載の医薬組成物。
- 個体においてベータ−カテニン遺伝子の発現を阻害するための医薬組成物であって、センス鎖とアンチセンス鎖とを含むＲＮＡｉ剤を含む治療有効量の組成物を含み、アンチセンス鎖が、表１に示すベータ−カテニンに特異的なＲＮＡｉ剤のアンチセンス鎖と０、１、２または３ヌクレオチド異なる少なくとも１５の連続したヌクレオチドを含む、医薬組成物。
- ベータ−カテニン関連疾患が、大腸腺腫症、結腸直腸癌、基底細胞癌腫、乳癌、腎癌、ウイルムス腫瘍、髄芽腫、卵巣癌、副腎皮質腫瘍、胃癌、肝癌、黒色腫、膵癌、前立腺癌、腎癌、異所性歯牙および味覚乳頭、皮膚癌、石灰化上皮腫、組織非形成性甲状腺癌腫および子宮癌肉腫、部分的無歯症、骨粗鬆症、老化、変性疾患、褥瘡ならびに慢性創傷および／または創傷治癒障害である、請求項１３に記載の医薬組成物。
- センス鎖とアンチセンス鎖とを含むＲＮＡｉ剤を含むＲＮＡｉ製剤において用いるための医薬であって、アンチセンス鎖が、表１に示すベータ−カテニンに特異的なＲＮＡｉ剤のアンチセンス鎖と０、１、２または３ヌクレオチド異なる少なくとも１５の連続したヌクレオチドを含む医薬。
- 薬学的に有効な製剤中の上記の任意の組成物。
- 治療有効量の請求項１に記載の組成物を個体に投与するステップを含む、個体においてベータ−カテニン関連疾患を処置する方法において用いるための、請求項１に記載の組成物。
- ベータ−カテニン関連疾患の処置のための医薬の製造における、請求項１に記載の組成物の使用。
- 全てのピリミジンが、２’Ｏ−メチル−改変ヌクレオチドである、請求項１に記載の組成物。
- 全てのピリミジンが、２’Ｏ−メチル−改変ヌクレオチドである、請求項５に記載の組成物。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261584530P | 2012-01-09 | 2012-01-09 | |
| US61/584,530 | 2012-01-09 | ||
| US201261598530P | 2012-02-14 | 2012-02-14 | |
| US61/598,530 | 2012-02-14 | ||
| PCT/IB2013/050159 WO2013105022A2 (en) | 2012-01-09 | 2013-01-08 | Organic compositions to treat beta-catenin-related diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015503608A JP2015503608A (ja) | 2015-02-02 |
| JP2015503608A5 true JP2015503608A5 (ja) | 2016-03-03 |
| JP6158833B2 JP6158833B2 (ja) | 2017-07-05 |
Family
ID=47720548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014551706A Active JP6158833B2 (ja) | 2012-01-09 | 2013-01-08 | ベータ−カテニン関連疾患を処置するための有機組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10023862B2 (ja) |
| EP (1) | EP2802658A2 (ja) |
| JP (1) | JP6158833B2 (ja) |
| CN (1) | CN104302768A (ja) |
| AU (1) | AU2013208720A1 (ja) |
| BR (1) | BR112014016870A2 (ja) |
| CA (1) | CA2860676A1 (ja) |
| HK (1) | HK1205758A1 (ja) |
| WO (1) | WO2013105022A2 (ja) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3134527B1 (en) * | 2014-04-22 | 2018-12-12 | Medizinische Hochschule Hannover | Lncrnas for therapy and diagnosis of angiogenesis |
| CA3017963A1 (en) | 2016-03-16 | 2017-09-21 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for the treatment of a beta-catenin-associated disease or disorder |
| EP3533450A4 (en) * | 2016-10-31 | 2020-06-17 | Samsung Life Public Welfare Foundation | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ISCHEMIA-REPERFUSION DAMAGE, CONTAINING BILIARY ACID |
| KR20200106513A (ko) | 2018-01-05 | 2020-09-14 | 다이서나 파마수이티컬, 인크. | 면역요법을 강화시키기 위하여 베타-카테닌 및 ido 발현의 감소 |
| EP3752614A4 (en) * | 2018-02-14 | 2021-11-10 | Deep Genomics Incorporated | OLIGONUCLEOTIDE THERAPY FOR WILSON'S DISEASE |
| CN111500694B (zh) * | 2019-01-31 | 2023-02-24 | 中国科学院脑科学与智能技术卓越创新中心 | Baz2b基因作为靶点在缓解衰老中的应用 |
| EP4259134A1 (en) * | 2020-12-09 | 2023-10-18 | The Regents Of The University Of Michigan | Compositions and methods for treating wnt-driven cancer |
| WO2022187263A2 (en) * | 2021-03-01 | 2022-09-09 | Steadman Philippon Research Institute | Mcm for gene therapy to activate wnt pathway |
| AU2022316139A1 (en) * | 2021-07-23 | 2024-01-18 | Alnylam Pharmaceuticals, Inc. | Beta-catenin (ctnnb1) irna compositions and methods of use thereof |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6696561B1 (en) | 1909-07-09 | 2004-02-24 | Basf Aktiengesellschaft | Corynebacterium glutamicum genes encoding proteins involved in membrane synthesis and membrane transport |
| US2779780A (en) | 1955-03-01 | 1957-01-29 | Du Pont | 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation |
| JPS6041077B2 (ja) | 1976-09-06 | 1985-09-13 | 喜徳 喜谷 | １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体 |
| US4261989A (en) | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US5030453A (en) | 1983-03-24 | 1991-07-09 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5032401A (en) | 1989-06-15 | 1991-07-16 | Alpha Beta Technology | Glucan drug delivery system and adjuvant |
| US5266573A (en) | 1989-08-07 | 1993-11-30 | Elf Sanofi | Trifluoromethylphenyltetrahydropyridines for the treatment and/or prophylaxis of intestinal motility disorders |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| EP0647450A1 (en) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
| US6977244B2 (en) | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| US5891467A (en) | 1997-01-31 | 1999-04-06 | Depotech Corporation | Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| CZ295108B6 (cs) | 1998-03-20 | 2005-05-18 | Benitec Australia Ltd | Syntetický gen obsahující dispergovanou nebo cizorodou deoxyribonukleovou molekulu a genový konstrukt obsahující tento syntetický gen |
| EP1143957A3 (en) | 1998-12-16 | 2002-02-27 | Warner-Lambert Company | Treatment of arthritis with mek inhibitors |
| EP2314700A1 (en) | 1999-01-28 | 2011-04-27 | Medical College of Georgia Research Institute, Inc | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| IL145778A0 (en) | 1999-04-21 | 2002-07-25 | American Home Prod | Methods and compositions for inhibiting the function of polynucleotide sequences |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| BR0012325A (pt) | 1999-07-09 | 2002-05-21 | American Home Prod | Métodos e composições para prevenção da formação de rna anormal durante a transcrição de uma sequência de plasmìdeo |
| DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
| DE10160151A1 (de) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
| RU2164944C1 (ru) | 1999-12-09 | 2001-04-10 | Институт молекулярной биологии им. В.А. Энгельгардта РАН | Способ изменения генетических свойств организма |
| GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| EP1272630A2 (en) | 2000-03-16 | 2003-01-08 | Genetica, Inc. | Methods and compositions for rna interference |
| GB2377221B (en) | 2000-03-17 | 2004-08-18 | Benitec Australia Ltd | Genetic silencing |
| AU2001260140A1 (en) | 2000-03-22 | 2001-10-03 | Avntis Pharma Deutschland Gmbh | Nematodes as model organisms for the investigation of neurodegenerative diseases, in particular parkinsons disease, uses and methods for the discovery of substances and genes which can be used in the treatment of the above disease states and identification of a nematode gene. |
| IL151928A0 (en) | 2000-03-30 | 2003-04-10 | Whitehead Biomedical Inst | Rna sequence-specific mediators of rna interference |
| EP1290161B1 (en) | 2000-05-30 | 2011-06-22 | Johnson & Johnson Research Pty Limited | METHODS FOR MEDIATING GENE SUPPRESION BY USING FACTORS THAT ENHANCE RNAi |
| US6680068B2 (en) | 2000-07-06 | 2004-01-20 | The General Hospital Corporation | Drug delivery formulations and targeting |
| US6960614B2 (en) | 2000-07-19 | 2005-11-01 | Warner-Lambert Company | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids |
| US20030166064A1 (en) | 2000-08-03 | 2003-09-04 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of colon cancer |
| ES2215494T5 (es) | 2000-12-01 | 2017-12-28 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Moléculas de RNA pequeñas que median la interferencia de RNA |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| EP1399189A1 (en) | 2001-06-11 | 2004-03-24 | Universite De Montreal | Compositions and methods for enhancing nucleic acid transfer into cells |
| AU2002324723B2 (en) | 2001-08-16 | 2007-10-25 | The Trustees Of The University Of Pennsylvania | Synthesis and use of reagents for improved DNA lipofection and/or slow release pro-drug and drug therapies |
| DE10230997A1 (de) | 2001-10-26 | 2003-07-17 | Ribopharma Ag | Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels |
| EP2407473A3 (en) | 2002-02-01 | 2012-03-21 | ARIAD Pharmaceuticals, Inc | Method for producing phosphorus-containing compounds |
| ATE443133T1 (de) | 2002-02-01 | 2009-10-15 | Life Technologies Corp | Oligonukleotidzusammensetzungen mit verbesserter effizienz |
| CA2477657C (en) | 2002-03-05 | 2011-04-26 | Merck Frosst Canada & Co./Merck Frosst Canada & Cie | Cathepsin cysteine protease inhibitors |
| AU2003224672B2 (en) | 2002-03-08 | 2010-02-04 | Eisai R&D Management Co., Ltd. | Macrocyclic compounds useful as pharmaceuticals |
| ES2407849T3 (es) | 2002-03-13 | 2013-06-14 | Array Biopharma, Inc. | Derivados de bencimidazol alquilados N3 como inhibidores de MEK |
| TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| DE60334618D1 (de) | 2002-06-28 | 2010-12-02 | Protiva Biotherapeutics Inc | Verfahren und vorrichtung zur herstellung von liposomen |
| AU2003279004B2 (en) | 2002-09-28 | 2009-10-08 | Massachusetts Institute Of Technology | Influenza therapeutic |
| EP1560931B1 (en) | 2002-11-14 | 2011-07-27 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| US7217807B2 (en) | 2002-11-26 | 2007-05-15 | Rosetta Genomics Ltd | Bioinformatically detectable group of novel HIV regulatory genes and uses thereof |
| ATE465255T1 (de) | 2002-11-26 | 2010-05-15 | Univ Massachusetts | Verabreichung von sirnas |
| US20040208921A1 (en) | 2003-01-14 | 2004-10-21 | Ho Rodney J. Y. | Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues |
| EP1605978B1 (en) * | 2003-03-07 | 2010-09-01 | Alnylam Pharmaceuticals Inc. | Therapeutic compositions |
| CA2521464C (en) | 2003-04-09 | 2013-02-05 | Alnylam Pharmaceuticals, Inc. | Irna conjugates |
| JP4912873B2 (ja) * | 2003-04-09 | 2012-04-11 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | ｉＲＮＡ複合体 |
| ES2559828T3 (es) | 2003-07-16 | 2016-02-16 | Protiva Biotherapeutics Inc. | ARN de interferencia encapsulado en lípidos |
| MXPA06002216A (es) | 2003-08-28 | 2006-04-27 | Novartis Ag | Interferencia de arn doble que tiene extremos romos y modificaciones 3'. |
| US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
| AU2005248147A1 (en) | 2004-05-11 | 2005-12-08 | Alphagen Co., Ltd. | Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same |
| US7740861B2 (en) | 2004-06-16 | 2010-06-22 | University Of Massachusetts | Drug delivery product and methods |
| SI1789390T1 (sl) | 2004-09-02 | 2012-05-31 | Genentech Inc | Piridilni inhibitorji hedgehog signalizacije |
| US20090012018A1 (en) * | 2004-09-13 | 2009-01-08 | Matthias Hebrok | Inhibition of pancretic cancer cell growth |
| CA2596845C (en) | 2005-02-10 | 2016-11-08 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of diagnosing and treating cancer using b-catenin splice variants |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| PL1912636T3 (pl) | 2005-07-21 | 2015-02-27 | Ardea Biosciences Inc | N-(aryloamino)sulfonamidowe inhibitory mek |
| AU2006308765B2 (en) | 2005-11-02 | 2013-09-05 | Arbutus Biopharma Corporation | Modified siRNA molecules and uses thereof |
| GB0608838D0 (en) | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
| US20100105134A1 (en) | 2007-03-02 | 2010-04-29 | Mdrna, Inc. | Nucleic acid compounds for inhibiting gene expression and uses thereof |
| WO2008109369A2 (en) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting tnf gene expression and uses thereof |
| AU2008244211B2 (en) | 2007-05-01 | 2014-08-21 | Santaris Pharma A/S | RNA antagonist compounds for the modulation of beta-catenin |
| JP5726520B2 (ja) | 2007-05-22 | 2015-06-03 | アークトゥラス・セラピューティクス・インコーポレイテッドＡｒｃｔｕｒｕｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 治療剤のためのｕｎａオリゴマー |
| WO2008156702A2 (en) * | 2007-06-15 | 2008-12-24 | Cequent Pharmaceuticals, Inc. | Bacteria mediated gene silencing |
| AR068402A1 (es) | 2007-09-12 | 2009-11-18 | Genentech Inc | Combinaciones de compuestos inhibidores de fosfoinositida 3-quinasa y agentes quimioterapeuticos y los metodos de uso |
| ES2439705T3 (es) | 2007-10-25 | 2014-01-24 | Genentech, Inc. | Proceso para la preparación de compuestos de tienopirimidina |
| US20100267626A1 (en) * | 2007-11-05 | 2010-10-21 | Novartis Ag | Methods and compositions for measuring wnt activation and for treating wnt-related cancers |
| JP5697988B2 (ja) | 2007-12-27 | 2015-04-08 | プロチバ バイオセラピューティクス インコーポレイティッド | 干渉ｒｎａを使用したポロ様キナーゼ発現のサイレンシング方法 |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| TWI455944B (zh) * | 2008-07-01 | 2014-10-11 | Daiichi Sankyo Co Ltd | 雙股多核苷酸 |
| EP2266550A1 (en) * | 2009-06-15 | 2010-12-29 | Institut Curie | Antagonists of ß-catenin for preventing and/or treating neurodegenerative disorders |
| CA2677068A1 (en) | 2009-09-01 | 2011-03-01 | Mdrna, Inc. | Nucleic acid compounds for inhibiting gene expression and uses thereof |
| CN102573914B (zh) | 2009-10-16 | 2016-06-29 | 大学健康网络 | 卟啉纳米囊泡 |
| KR101605932B1 (ko) * | 2009-12-18 | 2016-03-24 | 노파르티스 아게 | Ｈｓｆ1-관련 질환을 치료하기 위한 유기 조성물 |
| EP2591105B1 (en) * | 2010-07-06 | 2017-05-31 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of beta-catenin by double-stranded rna |
| US8518907B2 (en) * | 2010-08-02 | 2013-08-27 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) |
-
2013
- 2013-01-08 CN CN201380013297.9A patent/CN104302768A/zh active Pending
- 2013-01-08 AU AU2013208720A patent/AU2013208720A1/en not_active Abandoned
- 2013-01-08 CA CA2860676A patent/CA2860676A1/en not_active Abandoned
- 2013-01-08 EP EP13704633.0A patent/EP2802658A2/en active Pending
- 2013-01-08 JP JP2014551706A patent/JP6158833B2/ja active Active
- 2013-01-08 BR BR112014016870A patent/BR112014016870A2/pt not_active IP Right Cessation
- 2013-01-08 US US14/371,131 patent/US10023862B2/en active Active
- 2013-01-08 WO PCT/IB2013/050159 patent/WO2013105022A2/en active Application Filing
-
2015
- 2015-07-06 HK HK15106407.7A patent/HK1205758A1/xx unknown
-
2018
- 2018-06-13 US US16/007,517 patent/US20180282728A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015503608A5 (ja) | ||
| JP2014525435A5 (ja) | ||
| JP2015517466A5 (ja) | ||
| AU2013208720A1 (en) | RNAi agents to treat Beta-Catenin related diseases | |
| Bishr et al. | Overview of the latest treatments for castration-resistant prostate cancer | |
| Lai et al. | Synergistic inhibition of lung cancer cell invasion, tumor growth and angiogenesis using aptamer-siRNA chimeras | |
| Deplanque et al. | A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer | |
| Cassidy et al. | Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies | |
| JP2023093644A (ja) | アンジオテンシノーゲンの発現を調節するための化合物及び方法 | |
| MX2021005389A (es) | Formulaciones de nanoparticulas lipidicas. | |
| JP2013514321A5 (ja) | ||
| AR079494A1 (es) | Composiciones organicas para tratar las enfermedades relacionadas con el factor de choque por calor 1 hsf1 | |
| Roca-Alonso et al. | Breast cancer treatment and adverse cardiac events: what are the molecular mechanisms? | |
| JP2018512060A5 (ja) | ||
| JP2011168619A (ja) | 抗癌剤の併用による癌治療方法 | |
| US20120058978A1 (en) | Method for the treatment of central nervous system cancers and compositions related thereto | |
| JP2016511256A5 (ja) | ||
| Nishimura et al. | Effects of EUS-guided intratumoral injection of oligonucleotide STNM01 on tumor growth, histology, and overall survival in patients with unresectable pancreatic cancer | |
| JP2018536689A5 (ja) | ||
| MX2020005345A (es) | Un método para inhibir o reducir una infección viral por coronavirus. | |
| JP2016520593A5 (ja) | ||
| JP2020055884A (ja) | がんのためのグルフォスファミド組み合わせ療法 | |
| Sun et al. | Abiraterone acetate for metastatic castration‐resistant prostate cancer after docetaxel failure: A randomized, double‐blind, placebo‐controlled phase 3 bridging study | |
| JP2013525332A5 (ja) | ||
| Ishiguro et al. | Co-treatment of dichloroacetate, omeprazole and tamoxifen exhibited synergistically antiproliferative effect on malignant tumors: in vivo experiments and a case report. |